Healthcare Disparities in Atopic Dermatitis: Insights from TARGET DERM Registry (2023 abstract)

Challenge

Real-world data on racial and ethnic disparities in AD disease severity presentation, clinical outcomes, and access to advanced therapies in the diverse US patient population—drawn from a large prospective multi-site registry—were limited, preventing evidence-based health equity interventions.

Solution

The TARGET-DERM AD registry was analyzed to compare clinical disease severity metrics, patient-reported outcomes, and advanced systemic therapy utilization rates across Non-Hispanic White, Non-Hispanic Black, Hispanic, and Non-Hispanic Asian/Pacific Islander patient groups.

Impact

Documenting that Non-Hispanic Black and Hispanic patients have higher objective disease severity yet lower AST utilization rates creates a directly actionable evidence base for health equity programs, diverse clinical trial enrollment mandates, and payer policy advocacy in AD.